Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleJohnson & Johnson said the settlement covers about 76,000 claims (Reuters)Johnson & Johnson has announced a provisional settlement of an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. This landmark agreement aims to conclude a contentious legal battle that has plagued the pharmaceutical giant for a decade, encompassing approximately 76,000 claims. For the settlement to become final, it requires acceptance from 95 per cent of the ovarian cancer claimants across state or federal jurisdictions. J&J's vice president of litigation, Erik Haas, stated the company believes the claims are “meritless” but is willing to settle to achieve “closure” and focus on its core mission. The company expects to pay $3billion in 2027, with further payments in 2028, though an attorney involved in negotiations suggests the total payout could exceed $7 billion. In fullJohnson & Johnson to pay $5.5bn settlement over baby powder lawsuitsMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
Cosmetics giant to pay billions in baby powder lawsuit settlements
Jump to contentThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged inAllNewsSportCultureLifestyleJohnson & Johnson said the settlement covers about 76,000 claims (Reuters)Johnson & Johnson has announced a provisional settlement of an estimated $5.5 billion to resolve tens of thousands of lawsuits alleging its talc-based products caused ovarian cancer. This landmark agreement aims to conclude a contentious legal battle that has plagued the pharmaceutical giant for a decade, encompassing approximately 76,000 claims. For the settlement to become final, it requires acceptance from 95 per cent of the ovarian cancer claimants across state or federal jurisdictions. J&J's vice president of litigation, Erik Haas, stated the company believes the claims are “meritless” but is willing to settle to achieve “closure” and focus on its core mission. The company expects to pay $3billion in 2027, with further payments in 2028, though an attorney involved in negotiations suggests the total payout could exceed $7 billion. In fullJohnson & Johnson to pay $5.5bn settlement over baby powder lawsuitsMore bulletinsThank you for registeringPlease refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in
